SynapDx, a maker of a blood diagnostics test for autism spectrum disorders, nabbed $6 million in venture funding, enabling executives to proceed with a 600-patient prospective multicenter clinical study for the test. In a trial slated to begin in the 2013 second quarter, researchers will evaluate the measurement of RNA expression differences to accurately diagnose children at risk for autism spectrum disorders. The test is meant to fill a gap in both the diagnosis and treatment of autism, CEO Stanley Lapidus told FierceMedicalDevices. Report | Release